Magnetoporator™ Platform Development

About Sigma Genetics

Sigma Genetics is a private, pre-revenue platform technology company pioneering a magnetic field-based approach to intracellular delivery. Its core innovation, the Magnetoporator™, aims to overcome key limitations of existing transfection and electroporation methods by using magnetic induction to create nanosecond pulsed electric fields, potentially offering greater efficiency, scalability, and adjustability. The platform is positioned to serve the high-growth markets of cell and gene therapy development, drug discovery, and biomanufacturing. As an early-stage company, its success hinges on robust validation, strategic partnerships, and securing further funding to advance its technology toward commercial adoption.